Skip to content

Exploring the mechanism of TAM-induced paclitaxel resistance in breast cancer in the glutamine metabolic microenvironment using PTC microtumor models

Exploring the mechanism of TAM-induced paclitaxel resistance in breast cancer in the glutamine metabolic microenvironment using PTC microtumor models

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118964
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-02-14
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Breast Malignant Tumor Observation Group:None

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent form; 2. Perform biopsy to confirm the diagnosis of breast cancer; 3. Have clear immunohistochemical pathological results; 4. The color Doppler ultrasound of the heart indicates that the cardiac ejection fraction is within the normal range; 5. Eastern Cooperative Oncology Group (ECOG) scale physical condition <= 0-2 points; 6. Female, 18 years <= age <= 65 years; 7. Normal blood indicators

Exclusion criteria

Exclusion criteria: 1.Other malignant tumors have been combined, or one has been diagnosed with other malignant tumors within the past 5 years, but these have been fully treated and controlled. Skin basal cell carcinoma or squamous cell carcinoma, and cervical carcinoma in situ are excluded. 2.It is a serious disease that is not malignant, and it will affect the patient's compliance or put the patient in a dangerous state. 3.Concurrent with other anti-tumor treatments or currently participating in other clinical trials; 4.Dementia, intellectual abnormalities or any mental disorder that hinders the understanding of the informed consent form; 5.Severe liver dysfunction, with Child-Pugh grade C, and/or severe cardiac insufficiency, with cardiac function grade III or above;

Design outcomes

Primary

MeasureTime frame
Progression-free survival period;

Secondary

MeasureTime frame
Overall survival period;

Countries

China

Contacts

Public ContactXia Wenjie

Zhejiang Provincial People's Hospital

741558330@qq.com+86 571 8589 3551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026